Macclesfield-headquartered Bioscript Group has acquired scientific communications agency Meridian HealthComms to strengthen its medical communications offering.
Bioscript Group, an integrated healthcare communication company with offices across the EU and US, said the newly combined business will help to provide its clients with extended support across integrated medical communication programmes.
In March 2021, Bioscript Group announced significant new investment from Sovereign Capital Partners to drive the next phase of its growth plan, which includes increasing its geographic footprint and extending into strategic services.
Andrew Medley, CEO at Bioscript Group, said: “Meridian joining our Group means we can continue to build our skills, capabilities, services, as well as quickly widening the pool of clients we work with. Joining with other companies is part of our 5-year plan for growth.
“This is another important step on our growth journey as we will continue to expand our offering for our clients and team.”
Meridian HealthComms, which was founded in 2004 with offices in Manchester and Cheshire, provides scientific and clinical communications, strategic planning and brand management for its pharmaceutical and biotech clients.
Dave Andrews, Managing Director at Meridian HealthComms, added: “We are delighted to be joining the Bioscript Group. Combined with greater medical communications resources, our clients now have access to a broader scope of expertise across regulatory writing, value comms and market access to allow integrated communications support throughout the product lifecycle.”
